Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVGR OTCMKTS:ECIA NASDAQ:LLIT NASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.46 million shsN/AECIAEncision$0.30-21.5%$0.33$0.21▼$0.50$6.45M0.75,170 shs2,021 shsLLITLianluo Smart$42.55-2.2%$9.91$2.76▼$17.14$94.08M0.161.04 million shs2.59 million shsPSTVPlus Therapeutics$0.43+3.0%$0.50$0.16▼$2.31$40.99M0.665.65 million shs4.21 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-64.36%ECIAEncision-21.47%-13.79%+20.00%-7.01%-19.79%LLITLianluo Smart-1.09%+11.22%-56.94%+272.11%+5,510.73%PSTVPlus Therapeutics+2.95%-13.83%-32.30%+109.93%-71.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.46 million shsN/AECIAEncision$0.30-21.5%$0.33$0.21▼$0.50$6.45M0.75,170 shs2,021 shsLLITLianluo Smart$42.55-2.2%$9.91$2.76▼$17.14$94.08M0.161.04 million shs2.59 million shsPSTVPlus Therapeutics$0.43+3.0%$0.50$0.16▼$2.31$40.99M0.665.65 million shs4.21 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVGRAvinger0.00%0.00%0.00%0.00%-64.36%ECIAEncision-21.47%-13.79%+20.00%-7.01%-19.79%LLITLianluo Smart-1.09%+11.22%-56.94%+272.11%+5,510.73%PSTVPlus Therapeutics+2.95%-13.83%-32.30%+109.93%-71.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVGRAvinger 0.00N/AN/AN/AECIAEncision 0.00N/AN/AN/ALLITLianluo Smart 0.00N/AN/AN/APSTVPlus Therapeutics 3.20Buy$7.881,752.51% UpsideCurrent Analyst Ratings BreakdownLatest AVGR, ECIA, PSTV, and LLIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/3/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$5.008/18/2025PSTVPlus TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.006/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$9.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10ECIAEncision$6.55M0.77N/AN/A$0.14 per share2.14LLITLianluo Smart$380K247.57N/AN/A($0.59) per share-72.12PSTVPlus Therapeutics$5.82M7.25N/AN/A($1.52) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVGRAvinger-$18.32M-$11.06N/AN/AN/AN/AN/AN/AN/AECIAEncision-$220K-$0.02N/A∞N/A-4.34%-16.99%-7.45%11/12/2025 (Estimated)LLITLianluo Smart-$4.45MN/A0.00∞N/AN/AN/AN/AN/APSTVPlus Therapeutics-$12.98M-$2.24N/AN/AN/A-357.85%N/A-117.72%11/13/2025 (Estimated)Latest AVGR, ECIA, PSTV, and LLIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PSTVPlus Therapeutics-$0.09-$0.01+$0.08-$0.01$1.08 million$1.39 million7/10/2025Q4 2025ECIAEncisionN/A-$0.01N/A-$0.01N/A$1.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVGRAvingerN/AN/AN/AN/AN/AECIAEncisionN/AN/AN/AN/AN/ALLITLianluo SmartN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVGRAvingerN/AN/AN/AECIAEncision0.101.920.72LLITLianluo SmartN/A2.422.17PSTVPlus TherapeuticsN/A1.261.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVGRAvinger18.30%ECIAEncision8.20%LLITLianluo Smart28.75%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipAVGRAvinger42.80%ECIAEncision36.75%LLITLianluo Smart22.90%PSTVPlus Therapeutics0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVGRAvinger703.31 million1.89 millionNot OptionableECIAEncision3016.88 million10.68 millionNot OptionableLLITLianluo Smart62.21 millionN/ANot OptionablePSTVPlus Therapeutics2099.26 million98.48 millionNot OptionableAVGR, ECIA, PSTV, and LLIT HeadlinesRecent News About These CompaniesBrokerages Set Plus Therapeutics, Inc. (NASDAQ:PSTV) PT at $7.88September 15 at 2:13 AM | americanbankingnews.comHead to Head Analysis: Plus Therapeutics (NASDAQ:PSTV) and Gain Therapeutics (NASDAQ:GANX)September 8, 2025 | americanbankingnews.comPlus Therapeutics upgraded to Buy from Hold at D. Boral CapitalSeptember 3, 2025 | msn.comD. Boral Capital Upgrades Plus Therapeutics (PSTV)September 3, 2025 | msn.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPlus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comPlus Therapeutics Secures Nasdaq Compliance ExtensionAugust 26, 2025 | msn.comPlus Therapeutics, Inc. Confirms Compliance with Nasdaq Listing Rules Ahead of Grace Period ExpirationAugust 26, 2025 | quiverquant.comQPlus Therapeutics Regains Compliance with Applicable Nasdaq Listing CriteriaAugust 26, 2025 | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Director Acquires $53,900.00 in StockAugust 26, 2025 | insidertrades.comPlus Therapeutics price target lowered to $3 from $4 at MaximAugust 19, 2025 | msn.comPlus Therapeutics presents results from ReSPECT-LM Phase 1 trialAugust 19, 2025 | msn.comPlus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal MetastasesAugust 18, 2025 | globenewswire.comPlus Therapeutics Reports Strong Q2 2025 ResultsAugust 16, 2025 | msn.comPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics Reports $3M in Stock EquityAugust 16, 2025 | baystreet.caPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics reports stockholders’ equity in excess of $2.5MAugust 16, 2025 | msn.comPlus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 16, 2025 | finance.yahoo.comPlus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity RequirementsAugust 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Super Micro Computer Stock Hasn't Priced in Growth YetBy Gabriel Osorio-Mazilli | August 25, 20253 Undervalued Stocks Poised to Shine in the Next Market RallyBy Gabriel Osorio-Mazilli | September 8, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025AVGR, ECIA, PSTV, and LLIT Company DescriptionsAvinger NASDAQ:AVGRAvinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Encision OTCMKTS:ECIA$0.30 -0.08 (-21.47%) As of 09/16/2025 03:53 PM EasternEncision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.Lianluo Smart NASDAQ:LLITLianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.Plus Therapeutics NASDAQ:PSTV$0.43 +0.01 (+2.95%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$0.43 +0.01 (+1.39%) As of 06:42 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
